These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29105134)

  • 1. Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Feathers A; Swaminath A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1121. PubMed ID: 29105134
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Logan M; Ijaz UZ; Hansen R; Gerasimidis K; Russell RK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1119-1120. PubMed ID: 29105140
    [No Abstract]   [Full Text] [Related]  

  • 3. The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction.
    Logan M; Clark CM; Ijaz UZ; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; McDonald E; Milling S; Hansen RK; Gerasimidis K; Russell RK
    Aliment Pharmacol Ther; 2019 Sep; 50(6):664-674. PubMed ID: 31342536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Swaminath A; Feathers A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Oct; 46(7):645-656. PubMed ID: 28815649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse.
    Gerasimidis K; Nikolaou CK; Edwards CA; McGrogan P
    J Clin Gastroenterol; 2011 Mar; 45(3):234-9. PubMed ID: 20871409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is not a clinically useful marker for the prediction of the early nonresponse to exclusive enteral nutrition in pediatric patients with Crohn disease.
    Copova I; Hradsky O; Zarubova K; Gonsorcikova L; Potuznikova K; Lerchova T; Nevoral J; Bronsky J
    Eur J Pediatr; 2018 Nov; 177(11):1685-1693. PubMed ID: 30128744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Wall CL; Day AS
    Aliment Pharmacol Ther; 2019 Oct; 50(7):824-825. PubMed ID: 31532560
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Feathers A; Swaminath A; Ananthakrishnan AN; Falzon L; Li Ferry S
    Aliment Pharmacol Ther; 2017 Nov; 46(10):1026-1027. PubMed ID: 29052855
    [No Abstract]   [Full Text] [Related]  

  • 9. Exclusive and partial enteral nutrition for Crohn's disease - Authors' reply.
    Kugathasan S; Denson LA; Hyams JS
    Lancet; 2017 Sep; 390(10101):1486-1487. PubMed ID: 28952446
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin.
    Zubin G; Peter L
    Inflamm Bowel Dis; 2015 Jun; 21(6):1386-91. PubMed ID: 25851564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Compliance During Exclusive Enteral Nutrition on Faecal Calprotectin in Children With Crohn Disease.
    Mckirdy S; Russell RK; Svolos V; Gkikas K; Logan M; Hansen R; Gerasimidis K
    J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):801-804. PubMed ID: 35192573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary triggers of gut inflammation following exclusive enteral nutrition in children with Crohn's disease: a pilot study.
    Gkikas K; Logan M; Nichols B; Ijaz UZ; Clark CM; Svolos V; Gervais L; Duncan H; Garrick V; Curtis L; Buchanan E; Cardigan T; Armstrong L; Delahunty C; Flynn DM; Barclay AR; Tayler R; Milling S; Hansen R; Russell RK; Gerasimidis K
    BMC Gastroenterol; 2021 Dec; 21(1):454. PubMed ID: 34861829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Authors' reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn's Disease Behavior, Fecal Calprotectin and Quality of Life.
    Bryant RV; Schultz CG; Ooi S; Goess C; Costello SP; Vincent AD; Schoeman S; Lim A; Bartholomeusz FD; Travis SPL; Andrews JM
    Inflamm Bowel Dis; 2019 May; 25(6):e62-e63. PubMed ID: 30380064
    [No Abstract]   [Full Text] [Related]  

  • 14. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.
    Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
    Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome.
    Frivolt K; Schwerd T; Werkstetter KJ; Schwarzer A; Schatz SB; Bufler P; Koletzko S
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1398-407. PubMed ID: 24779671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive enteral nutrition and induction of remission of active Crohn's disease in children.
    Day AS; Burgess L
    Expert Rev Clin Immunol; 2013 Apr; 9(4):375-83; quiz 384. PubMed ID: 23557272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exclusive enteral nutrition in children with Crohn's disease.
    Day AS; Lopez RN
    World J Gastroenterol; 2015 Jun; 21(22):6809-16. PubMed ID: 26078556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.
    Lasson A; Strid H; Ohman L; Isaksson S; Olsson M; Rydström B; Ung KA; Stotzer PO
    J Crohns Colitis; 2014 Aug; 8(8):789-95. PubMed ID: 24418661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.